236 related articles for article (PubMed ID: 24697342)
41. Development and implementation of the population Fisher information matrix for the evaluation of population pharmacokinetic designs.
Retout S; Duffull S; Mentré F
Comput Methods Programs Biomed; 2001 May; 65(2):141-51. PubMed ID: 11275334
[TBL] [Abstract][Full Text] [Related]
42. Mixed models for data from thorough QT studies: part 1. assessment of marginal QT prolongation.
Schall R; Ring A
Pharm Stat; 2011; 10(3):265-76. PubMed ID: 21574242
[TBL] [Abstract][Full Text] [Related]
43. A linearization approach for the model-based analysis of combined aggregate and individual patient data.
Ravva P; Karlsson MO; French JL
Stat Med; 2014 Apr; 33(9):1460-76. PubMed ID: 24488864
[TBL] [Abstract][Full Text] [Related]
44. Knowledge-driven approaches for the guidance of first-in-children dosing.
Edginton AN
Paediatr Anaesth; 2011 Mar; 21(3):206-13. PubMed ID: 21129100
[TBL] [Abstract][Full Text] [Related]
45. Optimal population designs for PK models with serial sampling.
Gagnon R; Leonov S
J Biopharm Stat; 2005; 15(1):143-63. PubMed ID: 15702610
[TBL] [Abstract][Full Text] [Related]
46. An evaluation of population D-optimal designs via pharmacokinetic simulations.
Hooker AC; Foracchia M; Dodds MG; Vicini P
Ann Biomed Eng; 2003 Jan; 31(1):98-111. PubMed ID: 12572660
[TBL] [Abstract][Full Text] [Related]
47. Physiologically based pharmacokinetics (PBPK).
Espié P; Tytgat D; Sargentini-Maier ML; Poggesi I; Watelet JB
Drug Metab Rev; 2009; 41(3):391-407. PubMed ID: 19601719
[TBL] [Abstract][Full Text] [Related]
48. Designing simple PK-PD studies in children.
Thomson AH; Elliott HL
Paediatr Anaesth; 2011 Mar; 21(3):190-6. PubMed ID: 21040154
[TBL] [Abstract][Full Text] [Related]
49. The importance of drug-target residence time.
Zhang R; Monsma F
Curr Opin Drug Discov Devel; 2009 Jul; 12(4):488-96. PubMed ID: 19562645
[TBL] [Abstract][Full Text] [Related]
50. Optimization of individual and population designs using Splus.
Retout S; Mentré F
J Pharmacokinet Pharmacodyn; 2003 Dec; 30(6):417-43. PubMed ID: 15000423
[TBL] [Abstract][Full Text] [Related]
51. A two-step iterative algorithm for estimation in nonlinear mixed-effect models with an evaluation in population pharmacokinetics.
Mentré F; Gomeni R
J Biopharm Stat; 1995 Jul; 5(2):141-58. PubMed ID: 7581424
[TBL] [Abstract][Full Text] [Related]
52. Sample size calculations based on generalized estimating equations for population pharmacokinetic experiments.
Ogungbenro K; Aarons L; Graham G
J Biopharm Stat; 2006; 16(2):135-50. PubMed ID: 16584063
[TBL] [Abstract][Full Text] [Related]
53. Finding optimal design in nonlinear mixed effect models using multiplicative algorithms.
Seurat J; Tang Y; Mentré F; Nguyen TT
Comput Methods Programs Biomed; 2021 Aug; 207():106126. PubMed ID: 34038863
[TBL] [Abstract][Full Text] [Related]
54. A model-based approach to dose selection in early pediatric development.
Cella M; Gorter de Vries F; Burger D; Danhof M; Della Pasqua O
Clin Pharmacol Ther; 2010 Mar; 87(3):294-302. PubMed ID: 20107435
[TBL] [Abstract][Full Text] [Related]
55. Physiologically based pharmacokinetic (PBPK) modeling and simulation: applications in lead optimization.
Peters SA; Ungell AL; Dolgos H
Curr Opin Drug Discov Devel; 2009 Jul; 12(4):509-18. PubMed ID: 19562647
[TBL] [Abstract][Full Text] [Related]
56. Prediction discrepancies for the evaluation of nonlinear mixed-effects models.
Mentré F; Escolano S
J Pharmacokinet Pharmacodyn; 2006 Jun; 33(3):345-67. PubMed ID: 16284919
[TBL] [Abstract][Full Text] [Related]
57. How experimental errors influence drug metabolism and pharmacokinetic QSAR/QSPR models.
Wenlock MC; Carlsson LA
J Chem Inf Model; 2015 Jan; 55(1):125-34. PubMed ID: 25406036
[TBL] [Abstract][Full Text] [Related]
58. Advances in paediatric pharmacokinetics.
Knibbe CA; Krekels EH; Danhof M
Expert Opin Drug Metab Toxicol; 2011 Jan; 7(1):1-8. PubMed ID: 21117982
[TBL] [Abstract][Full Text] [Related]
59. Application of IVIVE and PBPK modeling in prospective prediction of clinical pharmacokinetics: strategy and approach during the drug discovery phase with four case studies.
Chen Y; Jin JY; Mukadam S; Malhi V; Kenny JR
Biopharm Drug Dispos; 2012 Mar; 33(2):85-98. PubMed ID: 22228214
[TBL] [Abstract][Full Text] [Related]
60. Impact of physiologically based pharmacokinetic modeling and simulation in drug development.
Shardlow CE; Generaux GT; Patel AH; Tai G; Tran T; Bloomer JC
Drug Metab Dispos; 2013 Dec; 41(12):1994-2003. PubMed ID: 24009310
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
